Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.62 |
| ▸ | RAB9A | P51151 | 9/20 | 0.62 |
| ▸ | GLS | O94925 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25056995 | 0.87 | ADORA1 (0.64) | NPC1RAB9AGLSPOLBSMN1; SMN2 | |
| SCHEMBL20964588 | 0.85 | NPC1 (0.59) | NPC1RAB9AGLSPOLBSMN1; SMN2 | |
| SCHEMBL17234165 | 0.84 | POLB (0.68) | NPC1RAB9AGLSPOLBSMN1; SMN2 | |
| SCHEMBL30920002 | 0.84 | POLB (0.68) | NPC1RAB9AGLSPOLBSMN1; SMN2 | |
| SCHEMBL4458535 | 0.81 | POLB (0.64) | NPC1RAB9APOLBSMN1; SMN2MEN1 | |
| SCHEMBL25402093 | 0.81 | RAB9A (0.58) | NPC1RAB9APOLBMEN1KMT2A | |
| SCHEMBL1981436 | 0.80 | BCHE (0.58) | NPC1RAB9AGLSPOLBSMN1; SMN2 | |
| SCHEMBL6640386 | 0.80 | POLB (0.62) | NPC1RAB9APOLBSMN1; SMN2MEN1 | |
| SCHEMBL11207220 | 0.80 | NPC1 (0.67) | NPC1RAB9APOLBSMN1; SMN2MEN1 | |
| SCHEMBL1822190 | 0.79 | NPC1 (0.58) | NPC1RAB9AGLSPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513068-B1 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-11 | — | — | EP | disclosed |
| US-8481547-B2 | Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-09 | — | — | US | disclosed |
| EP-2513068-A1 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110152287-A1 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075631-A1 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152287-A1 | SUBSTITUTED BENZOTHIAZOLE AND BENZOXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | DPP4, DPP7, DPP3 | NPC1 500/4885RAB9A 3547/4885GLS 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.